The Ceruloplasmin Transferrin Ratio in the Blood of Patients at Different Stages of Parkinson’s Disease View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-11

AUTHORS

M. G. Makletsova, G. T. Rikhireva, V. V. Poleschuk, S. N. Illarioshkin

ABSTRACT

The ratio of the concentrations of Cu2+-ceruloplasmin/Fe3+-transferrin in the blood plasma of 54 patients at different stages of Parkinson’s disease treated and not treated with L-DOPA was estimated by EPR-spectroscopy. It was established that in patients who suffer from Parkinson’s disease, the value of ceruloplasmin/ transferrin increased by 157% in comparison with the control group of clinically healthy people of the same age group. In patients with Parkinson’s disease, the ratio of ceruloplasmin/transferrin increased at stage 1 of the disease by 119%, at stage 2 by 117%, and at stage 3 by 135% in comparison with the control group. There was no statistically significant difference between the ratio of ceruloplasmin/transferrin in patients who received and did not recive L-DOPA replacement therapy. These data reveal changes in the functioning of the ceruloplasmin: transferrin system, which decreases the content of toxic ions of Fe2+ in the plasma of patients with Parkinson’s disease. These changes are a pathogenetically significant factor of Parkinson’s disease at all stages of the disease. More... »

PAGES

994-997

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1134/s0006350917060148

DOI

http://dx.doi.org/10.1134/s0006350917060148

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101228111


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Research Center for Neurology, 125367, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center for Neurology, 125367, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Makletsova", 
        "givenName": "M. G.", 
        "id": "sg:person.013770715544.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013770715544.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Semenov Institute of Chemical Physics, Russian Academy of Science, 119991, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.424930.8", 
          "name": [
            "Semenov Institute of Chemical Physics, Russian Academy of Science, 119991, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rikhireva", 
        "givenName": "G. T.", 
        "id": "sg:person.012561432254.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012561432254.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center for Neurology, 125367, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center for Neurology, 125367, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Poleschuk", 
        "givenName": "V. V.", 
        "id": "sg:person.012123205566.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012123205566.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center for Neurology, 125367, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center for Neurology, 125367, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Illarioshkin", 
        "givenName": "S. N.", 
        "id": "sg:person.07612205054.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07612205054.47"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11011-015-9721-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015393651", 
          "https://doi.org/10.1007/s11011-015-9721-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11940-016-0426-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012043093", 
          "https://doi.org/10.1007/s11940-016-0426-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02766076", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014586517", 
          "https://doi.org/10.1007/bf02766076"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-11", 
    "datePublishedReg": "2017-11-01", 
    "description": "The ratio of the concentrations of Cu2+-ceruloplasmin/Fe3+-transferrin in the blood plasma of 54 patients at different stages of Parkinson\u2019s disease treated and not treated with L-DOPA was estimated by EPR-spectroscopy. It was established that in patients who suffer from Parkinson\u2019s disease, the value of ceruloplasmin/ transferrin increased by 157% in comparison with the control group of clinically healthy people of the same age group. In patients with Parkinson\u2019s disease, the ratio of ceruloplasmin/transferrin increased at stage 1 of the disease by 119%, at stage 2 by 117%, and at stage 3 by 135% in comparison with the control group. There was no statistically significant difference between the ratio of ceruloplasmin/transferrin in patients who received and did not recive L-DOPA replacement therapy. These data reveal changes in the functioning of the ceruloplasmin: transferrin system, which decreases the content of toxic ions of Fe2+ in the plasma of patients with Parkinson\u2019s disease. These changes are a pathogenetically significant factor of Parkinson\u2019s disease at all stages of the disease.", 
    "genre": "article", 
    "id": "sg:pub.10.1134/s0006350917060148", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1017924", 
        "issn": [
          "0006-3509", 
          "1555-6654"
        ], 
        "name": "Biophysics", 
        "publisher": "Pleiades Publishing", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "62"
      }
    ], 
    "keywords": [
      "Parkinson's disease", 
      "control group", 
      "DOPA replacement therapy", 
      "blood of patients", 
      "plasma of patients", 
      "same age group", 
      "replacement therapy", 
      "patients", 
      "healthy people", 
      "transferrin ratio", 
      "age groups", 
      "disease", 
      "stage 3", 
      "significant differences", 
      "stage 1", 
      "blood plasma", 
      "stage 2", 
      "different stages", 
      "group", 
      "transferrin", 
      "significant factor", 
      "therapy", 
      "blood", 
      "DOPA", 
      "plasma", 
      "ceruloplasmin", 
      "stage", 
      "changes", 
      "ratio", 
      "functioning", 
      "factors", 
      "differences", 
      "comparison", 
      "people", 
      "concentration", 
      "data", 
      "transferrin system", 
      "values", 
      "content", 
      "system", 
      "concentration of Cu2", 
      "Fe2", 
      "ions", 
      "Cu2", 
      "toxic ions", 
      "Fe3", 
      "ceruloplasmin/ transferrin", 
      "ceruloplasmin/transferrin", 
      "Ceruloplasmin Transferrin Ratio"
    ], 
    "name": "The Ceruloplasmin Transferrin Ratio in the Blood of Patients at Different Stages of Parkinson\u2019s Disease", 
    "pagination": "994-997", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101228111"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1134/s0006350917060148"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1134/s0006350917060148", 
      "https://app.dimensions.ai/details/publication/pub.1101228111"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_755.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1134/s0006350917060148"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1134/s0006350917060148'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1134/s0006350917060148'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1134/s0006350917060148'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1134/s0006350917060148'


 

This table displays all metadata directly associated to this object as RDF triples.

143 TRIPLES      22 PREDICATES      78 URIs      67 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1134/s0006350917060148 schema:about anzsrc-for:11
2 anzsrc-for:1109
3 schema:author N23c70ffba6a54b42b83d916c115bb5d1
4 schema:citation sg:pub.10.1007/bf02766076
5 sg:pub.10.1007/s11011-015-9721-x
6 sg:pub.10.1007/s11940-016-0426-1
7 schema:datePublished 2017-11
8 schema:datePublishedReg 2017-11-01
9 schema:description The ratio of the concentrations of Cu2+-ceruloplasmin/Fe3+-transferrin in the blood plasma of 54 patients at different stages of Parkinson’s disease treated and not treated with L-DOPA was estimated by EPR-spectroscopy. It was established that in patients who suffer from Parkinson’s disease, the value of ceruloplasmin/ transferrin increased by 157% in comparison with the control group of clinically healthy people of the same age group. In patients with Parkinson’s disease, the ratio of ceruloplasmin/transferrin increased at stage 1 of the disease by 119%, at stage 2 by 117%, and at stage 3 by 135% in comparison with the control group. There was no statistically significant difference between the ratio of ceruloplasmin/transferrin in patients who received and did not recive L-DOPA replacement therapy. These data reveal changes in the functioning of the ceruloplasmin: transferrin system, which decreases the content of toxic ions of Fe2+ in the plasma of patients with Parkinson’s disease. These changes are a pathogenetically significant factor of Parkinson’s disease at all stages of the disease.
10 schema:genre article
11 schema:inLanguage en
12 schema:isAccessibleForFree false
13 schema:isPartOf N0d2ff858ed9a452786a6242215ed77e2
14 N49207bef31bb44aeb99314486da0368f
15 sg:journal.1017924
16 schema:keywords Ceruloplasmin Transferrin Ratio
17 Cu2
18 DOPA
19 DOPA replacement therapy
20 Fe2
21 Fe3
22 Parkinson's disease
23 age groups
24 blood
25 blood of patients
26 blood plasma
27 ceruloplasmin
28 ceruloplasmin/ transferrin
29 ceruloplasmin/transferrin
30 changes
31 comparison
32 concentration
33 concentration of Cu2
34 content
35 control group
36 data
37 differences
38 different stages
39 disease
40 factors
41 functioning
42 group
43 healthy people
44 ions
45 patients
46 people
47 plasma
48 plasma of patients
49 ratio
50 replacement therapy
51 same age group
52 significant differences
53 significant factor
54 stage
55 stage 1
56 stage 2
57 stage 3
58 system
59 therapy
60 toxic ions
61 transferrin
62 transferrin ratio
63 transferrin system
64 values
65 schema:name The Ceruloplasmin Transferrin Ratio in the Blood of Patients at Different Stages of Parkinson’s Disease
66 schema:pagination 994-997
67 schema:productId N0f6251182b8b4306ae4225048b533518
68 Na37ddb6df0824012b98dd013c043de0d
69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101228111
70 https://doi.org/10.1134/s0006350917060148
71 schema:sdDatePublished 2021-12-01T19:41
72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
73 schema:sdPublisher Na49a404af2434f6aa9125c55547c2c52
74 schema:url https://doi.org/10.1134/s0006350917060148
75 sgo:license sg:explorer/license/
76 sgo:sdDataset articles
77 rdf:type schema:ScholarlyArticle
78 N0adbcdbd2e3949ab876407c76227be9c rdf:first sg:person.012123205566.72
79 rdf:rest N5c852e98cc974367bd0b9afea3d23132
80 N0d2ff858ed9a452786a6242215ed77e2 schema:volumeNumber 62
81 rdf:type schema:PublicationVolume
82 N0f6251182b8b4306ae4225048b533518 schema:name doi
83 schema:value 10.1134/s0006350917060148
84 rdf:type schema:PropertyValue
85 N1996b75a39404a02b39b47f5bde0ed95 rdf:first sg:person.012561432254.46
86 rdf:rest N0adbcdbd2e3949ab876407c76227be9c
87 N23c70ffba6a54b42b83d916c115bb5d1 rdf:first sg:person.013770715544.19
88 rdf:rest N1996b75a39404a02b39b47f5bde0ed95
89 N49207bef31bb44aeb99314486da0368f schema:issueNumber 6
90 rdf:type schema:PublicationIssue
91 N5c852e98cc974367bd0b9afea3d23132 rdf:first sg:person.07612205054.47
92 rdf:rest rdf:nil
93 Na37ddb6df0824012b98dd013c043de0d schema:name dimensions_id
94 schema:value pub.1101228111
95 rdf:type schema:PropertyValue
96 Na49a404af2434f6aa9125c55547c2c52 schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
99 schema:name Medical and Health Sciences
100 rdf:type schema:DefinedTerm
101 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
102 schema:name Neurosciences
103 rdf:type schema:DefinedTerm
104 sg:journal.1017924 schema:issn 0006-3509
105 1555-6654
106 schema:name Biophysics
107 schema:publisher Pleiades Publishing
108 rdf:type schema:Periodical
109 sg:person.012123205566.72 schema:affiliation grid-institutes:grid.465332.5
110 schema:familyName Poleschuk
111 schema:givenName V. V.
112 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012123205566.72
113 rdf:type schema:Person
114 sg:person.012561432254.46 schema:affiliation grid-institutes:grid.424930.8
115 schema:familyName Rikhireva
116 schema:givenName G. T.
117 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012561432254.46
118 rdf:type schema:Person
119 sg:person.013770715544.19 schema:affiliation grid-institutes:grid.465332.5
120 schema:familyName Makletsova
121 schema:givenName M. G.
122 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013770715544.19
123 rdf:type schema:Person
124 sg:person.07612205054.47 schema:affiliation grid-institutes:grid.465332.5
125 schema:familyName Illarioshkin
126 schema:givenName S. N.
127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07612205054.47
128 rdf:type schema:Person
129 sg:pub.10.1007/bf02766076 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014586517
130 https://doi.org/10.1007/bf02766076
131 rdf:type schema:CreativeWork
132 sg:pub.10.1007/s11011-015-9721-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1015393651
133 https://doi.org/10.1007/s11011-015-9721-x
134 rdf:type schema:CreativeWork
135 sg:pub.10.1007/s11940-016-0426-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012043093
136 https://doi.org/10.1007/s11940-016-0426-1
137 rdf:type schema:CreativeWork
138 grid-institutes:grid.424930.8 schema:alternateName Semenov Institute of Chemical Physics, Russian Academy of Science, 119991, Moscow, Russia
139 schema:name Semenov Institute of Chemical Physics, Russian Academy of Science, 119991, Moscow, Russia
140 rdf:type schema:Organization
141 grid-institutes:grid.465332.5 schema:alternateName Research Center for Neurology, 125367, Moscow, Russia
142 schema:name Research Center for Neurology, 125367, Moscow, Russia
143 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...